Literature DB >> 17522237

Sentinel lymph node biopsy in male patients with early breast cancer.

Oreste Gentilini1, Eduardo Chagas, Stefano Zurrida, Mattia Intra, Concetta De Cicco, Giovanna Gatti, Luzemira Silva, Giuseppe Renne, Enrico Cassano, Umberto Veronesi.   

Abstract

Mastectomy with axillary dissection is still the most commonly recommended procedure for male breast cancer. The aim of this study was to retrospectively evaluate our experience in 32 male patients with early breast cancer who underwent sentinel lymph node biopsy (SLNB) and axillary dissection only in cases of metastases in the sentinel lymph node (SLN). The median age was 58 years (range, 33-80). Lymphoscintigraphy was successful in all patients, with a mean number of visualized SLNs per patient of 1.3 (range, 1-2). At surgery, the identification rate of the SLN was 100%, with a mean number of removed SLNs per patient of 1.5 (range, 1-3). Twenty-six patients had negative SLNs, six patients had positive SLNs. Two patients with metastatic SLNs had additional positive nodes. After a median follow-up of 30 months (range, 1-63) no axillary reappearance of the disease occurred. As with women, we recommend SLNB in male patients with breast cancer and clinically negative axilla.

Entities:  

Mesh:

Year:  2007        PMID: 17522237     DOI: 10.1634/theoncologist.12-5-512

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  14 in total

Review 1.  Male Breast Cancer.

Authors:  Metin Yalaza; Aydın İnan; Mikdat Bozer
Journal:  J Breast Health       Date:  2016-01-01

Review 2.  Current status of sentinel lymph-node biopsy in patients with breast cancer.

Authors:  Gang Cheng; Stephanie Kurita; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-11       Impact factor: 9.236

3.  Multidisciplinary meeting on male breast cancer: summary and research recommendations.

Authors:  Larissa A Korde; Jo Anne Zujewski; Leah Kamin; Sharon Giordano; Susan Domchek; William F Anderson; John M S Bartlett; Karen Gelmon; Zeina Nahleh; Jonas Bergh; Bruno Cutuli; Giancarlo Pruneri; Worta McCaskill-Stevens; Julie Gralow; Gabriel Hortobagyi; Fatima Cardoso
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

4.  Sentinel Lymph Node Biopsy in Early Breast Cancer: The Experience of the European Institute of Oncology in Special Clinical Scenarios.

Authors:  Antonio Toesca; Alberto Luini; Paolo Veronesi; Mattia Intra; Oreste Gentilini
Journal:  Breast Care (Basel)       Date:  2011-06-03       Impact factor: 2.860

5.  Invasive ductal breast carcinoma underneath a lipoma in a male patient.

Authors:  James Landero; Khasha Touloei; Bradley P Glick
Journal:  J Clin Aesthet Dermatol       Date:  2012-10

6.  A Clinicopathological Evaluation of Male Patients with Breast Cancer.

Authors:  Enver Ilhan; Bakir Bati; Ali Alemdar; Ali Coskun; Arsenal Sezgin; Mehmet Yildirim; Omer Engin; Mete Purten
Journal:  Breast Care (Basel)       Date:  2009-10-01       Impact factor: 2.860

7.  Male breast cancer: 10-year experience at mansoura university hospital in egypt.

Authors:  Wafaa El-Beshbeshi; Engy M Abo-Elnaga
Journal:  Cancer Biol Med       Date:  2012-03       Impact factor: 4.248

Review 8.  Male breast cancer: is the scenario changing.

Authors:  Kaiyumars B Contractor; Kanchan Kaur; Gabriel S Rodrigues; Dhananjay M Kulkarni; Hemant Singhal
Journal:  World J Surg Oncol       Date:  2008-06-16       Impact factor: 2.754

9.  Computed tomographic lymphography for sentinel lymph node biopsy in male breast cancer: report of two cases.

Authors:  Naoki Hashimoto; Yurie Kudo; Michihiro Kurushima; Yamato Suzuki; Takafumi Yachi; Tomohisa Tokura; Yutaka Umehara; Shinsuke Nishikawa; Kenichi Takahashi; Takayuki Morita; Fumiko Narita
Journal:  Springerplus       Date:  2013-07-29

10.  Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.

Authors:  Piera Gargiulo; Matilde Pensabene; Monica Milano; Grazia Arpino; Mario Giuliano; Valeria Forestieri; Caterina Condello; Rossella Lauria; Sabino De Placido
Journal:  BMC Cancer       Date:  2016-07-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.